I like this line from the Griffin report...

"Since metformin, which is the first-line therapy, is typically effective for only about 12months, the second study should expand Afrezza’s market to virtually the entire diabetic population."

http://www.griffinsecurities.com/upload/reports/Griffin_MNKD_Research_Note_08Nov11.pdf